To produce an anti-tumor immune response, the effector immune cells need to recognize tumor antigens presented by tumor cells directly or by antigen-presenting cells (APCs) via major histocompatibility complex (MHC) on the cell surface. This evidence concerns the gene HLA-C and neoplasm.